Proteoglycan-4 potentiates the antitumor efficacy of regorafenib in an orthotopic model of hepatocellular carcinoma
PRG4 demonstrated antitumor activities in vivo and shows promise as an adjuvant to enhance therapeutic interventions in HCC.
Authors
- Nicolò Schena
- Davide Guido (ORCID: https://orcid.org/0000-0002-3291-3686)
- Livianna Carrieri (ORCID: https://orcid.org/0000-0001-6769-9520)
- Francesco Dituri (ORCID: https://orcid.org/0000-0002-7943-3698)
- Emanuele Piccinno (ORCID: https://orcid.org/0000-0002-7988-1917)
- Giusy Bianco
- Asma Munir (ORCID: https://orcid.org/0000-0001-6926-0773)
- Giusi Caragnano (ORCID: https://orcid.org/0009-0008-2276-5035)
- Gianluigi Giannelli (ORCID: https://orcid.org/0000-0002-5140-8060)
- Grazia Serino (ORCID: https://orcid.org/0000-0002-2971-0802)
- Raffaele Armentano (ORCID: https://orcid.org/0000-0003-1661-5504)
- Domenico Mastronardi
Institutions
- Gastroenterology Hospital "Saverio de Bellis" (IT)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1186/s13046-025-03575-5
- Primary Topic
- Fibroblast Growth Factor Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00